Mecobalamin For ALS Among New Japan Recommendations

Japan has issued positive approval recommendations for 10 new drugs, including Catalyst’s Firdapse and Idorsia/Nxera’s Quviviq, as well as a global-first nod for mecobalamin in ALS. 

Eisai's ultra-high dose of mecobalamin has got closer to its global first approval for ALS.
Eisai's ultra-high dose mecobalamin a step closer to global-first approval for ALS • Source: Shutterstock

An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has recommended the approval of eight new drugs, including a global-first indication for Eisai Co., Ltd.’s ultra-high dose formulation of mecobalamin for amyotrophic lateral sclerosis (ALS).

The list of positive recommendations also gives a nod to Nxera Pharm (formerly Sosei Group Corp.)/Idorsia Pharmaceuticals Ltd’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Asia

Leqembi Facing 15% Price Cut In Japan

 
• By 

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By 

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By 

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.